1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Sun Pharma Acquires Checkpoint

M&A Deal Summary

Sun Pharma Acquires Checkpoint

On March 9, 2025, Sun Pharma acquired life science company Checkpoint for 355M USD

Acquisition Highlights
  • This is Sun Pharma’s 10th transaction in the Life Science sector.
  • This is Sun Pharma’s 4th largest (disclosed) transaction.
  • This is Sun Pharma’s 7th transaction in the United States.
  • This is Sun Pharma’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2025-03-09
Target Checkpoint
Sector Life Science
Buyer(s) Sun Pharma
Deal Type Add-on Acquisition
Deal Value 355M USD
Advisor(s) Locust Walk Partners (Financial)
Alston & Bird (Legal)

Target

Checkpoint

Waltham, Massachusetts, United States
Checkpoint is a commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. It has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Checkpoint is based in Waltham, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Sun Pharma

Mumbai, India
Category Company
Founded 1983
Sector Life Science
Employees43,000
Revenue 520.4B INR (2025)
DESCRIPTION

Sun Pharma is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores, and gift/specialty stores. Sun Pharma was founded in 1983 and is based in Mumbai, Maharashtra.

DEAL STATS #
Overall 15 of 15
Sector: Life Science M&A 10 of 10
Type: Add-on Acquisition M&A Deals 8 of 8
State: Massachusetts M&A 4 of 4
Country: United States M&A 7 of 7
Year: 2025 M&A 1 of 1
Size (of disclosed) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-19 Concert Pharmaceuticals

Lexington, Massachusetts, United States

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor. The company has successfully completed two Phase 3 trials with deuruxolitinib in adults with Alopecia Areata, a serious autoimmune dermatological disease. It is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. Concert Pharmaceuticals was founded in 2006 and is based in Lexington, Massachusetts.

Buy $576M
Mergr

Solution for

Product

Company

Legal